bfe67bb53c3c532ef4237fa3323691ae27404769
ST6GALNAC5 is a type II transmembrane protein with the following structural organization: [@huang2022]
| Property |
Value |
| Gene Symbol |
ST6GALNAC5 (SIAT7B) |
| UniProt |
Q9UNP4 |
| Molecular Weight |
~50 kDa |
| Length |
450 amino acids |
| Subcellular Localization |
Golgi apparatus (membrane-bound) |
| Protein Family |
CAZy family GH29 (alpha-N-acetylgalactosaminidases) + GT38 (alpha-2,6-sialyltransferases) |
| Chromosome |
1p31.3 |
Domain organization:
- N-terminal transmembrane domain: Anchors the enzyme in the Golgi membrane
- Stem region: Short region connecting TM to catalytic domain
- Catalytic domain: Contains the sialyltransferase active site with a DXH motif and a second histidine for donor substrate binding
ST6GALNAC5 differs from the related ST6GAL1 (widely expressed in liver and many tissues) in its cell type specificity, substrate preference, and brain-enriched expression pattern. [@boscher2021]
bfe67bb53c3c532ef4237fa3323691ae27404769
Under physiological conditions, ST6GALNAC5 participates in glycosylation remodeling that supports normal astrocyte function: [@voss2023]
Astrocytes use sialylated glycoproteins to communicate with neurons:
- Surface signaling: Sialylated proteins on astrocyte surface interact with siglec receptors on neurons
- Synaptic support: Normal astrocyte sialylation contributes to synaptic maintenance and function
- Ion regulation: Astrocyte sialylated proteins participate in potassium siphoning
During development, ST6GALNAC5 is involved in:
- Neuronal migration (sialylated proteins on glial cells guide migrating neurons)
- Synaptogenesis (astrocyte-derived sialylated factors promote synapse formation)
- Axon guidance (glycosylation patterns create molecular cues)
The enzyme maintains the balance of sialylated glycoconjugates in the brain:
- Modifies surface proteins of astrocytes with alpha-2,6-linked sialic acid
- Sialylated proteins can regulate complement activation and immune recognition
- Contributes to the glycocalyx of astrocyte end-feet at the neurovascular unit
In AD, astrocytes become reactive (astrogliosis) and ST6GALNAC5 expression is significantly upregulated: [@stgalnac2024]
- Aβ exposure response: Exposure to amyloid-beta oligomers induces ST6GALNAC5 transcription
- Synaptic toxicity mechanism: Elevated ST6GALNAC5 in astrocytes drives synaptic loss through a non-cell-autonomous mechanism
- Sialic acid accumulation: Increased ST6GALNAC5 leads to hyper-sialylation of astrocyte surface proteins, altering their signaling properties
A 2024 Nature Neuroscience study demonstrated: [@stgalnac2024]
- ST6GALNAC5 is specifically upregulated in reactive astrocytes in AD brains
- Astrocyte-specific knockdown of ST6GALNAC5 improves spatial memory in 5xFAD AD mouse models
- Synaptic integrity is preserved in the hippocampus when ST6GALNAC5 is reduced
- Neuroinflammation is reduced through modulation of astrocyte activation state
- Astrocyte-to-neuron signaling is normalized when ST6GALNAC5 is silenced
The current model proposes: [@li2023]
flowchart TD
A["Amyloid-beta Oligomers"] --> B["Astrocyte Reactivity"]
B --> C["ST6GALNAC5 Upregulation"]
C --> D["Alpha-2,6 Sialylation Increase"]
D --> E1["Altered Siglec Receptor Signaling"]
D --> E2["Disrupted Neuron-Astrocyte Communication"]
D --> E3["Enhanced Immune Recognition"]
E1 --> F["Astrocyte Dysfunction"]
E2 --> G["Synaptic Dysfunction & Loss"]
E3 --> H["Chronic Neuroinflammation"]
F --> G
H --> G
style A fill:#e1f5fe,stroke:#333
style G fill:#ffcdd2,stroke:#333
style C fill:#fff3e0,stroke:#333
- Siglec receptor dysregulation: Sialylated astrocyte proteins engage inhibitory Siglec receptors on neurons, suppressing survival signaling
- Cytokine dysregulation: ST6GALNAC5 knockdown reduces IL-1β, TNF-α, and IL-6 release from astrocytes
- Synaptic protein loss: Presynaptic markers (synaptophysin, vGLUT1) are preserved when ST6GALNAC5 is reduced
- ST6GALNAC5 expression is induced by Aβ oligomers through NF-κB pathway activation
- Sialylated proteins may facilitate Aβ aggregation or its effects on glia
- Reduction of ST6GALNAC5 protects against Aβ-induced synaptic loss
- Indirect effects through neuroinflammation
- Synaptic protection appears partially independent of tau pathology
- May affect tau spread by modulating astrocyte-mediated phagocytosis
ST6GALNAC5 is an attractive therapeutic target because: [@kremer2021]
- Astrocyte-specific expression provides tissue/cell type selectivity
- Knockdown shows clear benefit in animal models of AD
- Astrocyte-targeting is feasible with AAV vectors (e.g., GFAP promoter-driven shRNA)
| Approach |
Status |
Notes |
| AAV-mediated knockdown |
Preclinical |
shRNA or siRNA targeting ST6GALNAC5 under GFAP promoter |
| Small molecule inhibitors |
Early discovery |
Challenge: targeting Golgi enzyme |
| Antibody-based approaches |
Theoretical |
Limited by intracellular enzyme location |
| Gene therapy |
Preclinical |
CRISPR-based approaches being explored |
ST6GALNAC5 is part of a broader picture linking glycosylation to neurodegeneration: [@boscher2021]
- Altered glycosylation is observed across neurodegenerative diseases
- Siglec receptors (sialic acid-binding immunoglobulin-type lectins) are key mediators of glia-neuron cross-talk
- Sialic acid metabolism is increasingly recognized as a modulator of neuroinflammation
Other sialyltransferases implicated in brain function include:
- ST3GAL1/ST3GAL2: Alpha-2,3-sialylation; roles in synaptic gangliosides
- ST6GAL1: Systemic sialylation; linked to inflammation
- ST8SIA1/ST8SIA2: Polysialic acid synthesis; neural plasticity
bfe67bb53c3c532ef4237fa3323691ae27404769